Articles tagged "Hyperglycemia"

2018 American Transplant Congress
Comprehensive Efficacy Analysis of Pancreas Transplantation Alone for Type 1 Diabetes Mellitus
Y. Kudva,¹ V. Dadlani,¹ B. Smith,³ K. Bebjakova,¹ P. Dean,² M. Stegall.²
¹Division of Endocrinology, Mayo Clinic, Rochester, MN; ²Department of Transplantation Surgery, Mayo Clinic, Rochester, MN; ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Introduction: Pancreas transplantation alone (PTA) is an accepted procedure for selected patients with type 1 diabetes mellitus (T1D). However, limited data exist regarding long term…
2018 American Transplant Congress
Comparison of Glycemic Control in Type 1 and Type 2 Diabetic Patients after Pancreas Transplantation
O. Andacoglu,¹ A. Murthy,² J. Ahn,³ J. Verbesey,¹ S. Ghasemian,¹ M. Cooper,¹ P. Abrams.¹
¹Transplant, Medstar Georgetown Transplant Institute, Washington, DC; ²School of Medicine, Georgetown University, Washington, DC; ³Biopstatistics, Georgetown University, Washington, DC.
Background: Pancreas transplant remains controversial for type 2 diabetic (T2DM) patients.Aim: To compare glycemic control following pancreas transplantation between T1 and T2 DM patients.Methods: 52…
2018 American Transplant Congress
Effect of Conversion to CTLA4Ig Treatment on Tacrolimus-Induced Diabetic Rats
J. Il,¹ L. Jin,¹ K. Luo,¹ S. Lim,¹ Y. Shin,¹ E. Ko,^1,2 B. Chung,^1,2 C. Yang.^1,2
¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea; ²Transplant Research Center, The Catholic University of Korea, Seoul, Republic of Korea.
Background: The effect of conversion to cytotoxic T-lymphocyte-associated protein 4 immunoglobulin (CTLA4Ig) treatment on tacrolimus (TAC)-induced renal dysfunction is well known, but its effect on…
2017 American Transplant Congress
Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes (T1D) Post Renal Transplantation.
J. Markmann, R. Alejandro, M. Bellin, N. Bridges, W. Clarke, T. Eggerman, E. Foster, B. Hering, D. Kaufman, O. Korsgren, X. Luo, A. Naji, J. Oberholzer, A. Posselt, M. Rickels, C. Ricordi, M. Robien, P. Senior, A. Shapiro, N. Turgeon.
CIT Consortium
Introduction: From a risk-benefit perspective, patients with type 1 diabetes (T1D) who are already obligated to long-term immunosuppression to support a kidney transplant and who…
2017 American Transplant Congress
Novel Therapies for Diabetic Kidney Disease.
M. Nguyen, K. Kodama, M. Sarwal.
University of California, San Francisco, San Francisco, CA
Introduction: The development and progression of diabetic kidney disease (DKD) is thought to involve a combination of hemodynamic, metabolic, ischemic, and inflammatory factors; however, the…
2017 American Transplant Congress
Impairment of Glucose Tolerance After Pediatric Kidney Transplant Is Associated with Worse Systemic Insulin Sensitivity Rather Than Fall in Insulin Secretion.
D. Iwami, K. Hotta, H. Sasaki, T. Hirose, H. Higuchi, Y. Takada, N. Shinohara.
Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Hokkaido, Japan
Introduction and Objective: Tacrolimus and steroid are considered to affect insulin secretion and insulin sensitivity, respectively, resulting in worse glucose tolerance after pediatric kidney transplant…
2017 American Transplant Congress
The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes.
C. Reuter,¹ R.-A. Lee,¹ R. Watkins,³ S. Lieber,² K. Szempruch,¹ D. Gerber,⁴ G. DeCherney,² A. Barritt IV.²
¹Department of Pharmacy, UNC Health Care, Chapel Hill, NC; ²Department of Medicine, UNC Health Care, Chapel Hill, NC; ³UNC Center for Transplant Care, UNC Health Care, Chapel Hill, NC; ⁴Department of Surgery, UNC Health Care, Chapel Hill, NC
Introduction: As the prevalence of diabetes (DM) increases in the general population, it is also increasing in the transplant (Tx) population. Post-transplant diabetes (PTDM) has…
2016 American Transplant Congress
Continuous Glucose Monitoring in the First 6 Weeks After Transplantation in Pancreas Transplant Recipients.
K. Bonner,¹ V. Dadlani,² P. Thapa,² M. Stegall,¹ Y. Kudva.²
¹Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Rochester; ²Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester.
Introduction The maturation of Continuous glucose monitoring (CGM) technology enables accurate characterization of daily glucose control. We investigated glucose control using CGM in the first…
2016 American Transplant Congress
Effect on Endothelial function when Hyperglycemia Is Reversed by Single Pancreas Transplantation.
T. Halden,^1,2 I. Eide,^1,2 D. Dahle,¹ A. Åsberg,^1,3 A. Reisæter,¹ T. Jenssen,^1,4 A. Hartmann.^1,2
¹Department of Transplant Medicine, Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ³Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway; ⁴Metabolic and Renal Research Group, UiT, The Arctic University of Norway, Tromsø, Norway.
Background: Endothelial dysfunction is a predictor for future cardiovascular disease. We have previously published that endothelial function improves in renal transplant recipients with post-transplantation diabetes…
2016 American Transplant Congress
Can We Predict New-Onset Diabetes After Transplantation Previously?
R. Imamura,¹ K. Tsutahara,² S. Nakazawa,¹ Y. Kakuta,¹ T. Abe,¹ T. Takao,² N. Ichimaru,³ S. Yamaguchi,² S. Takahara,³ N. Nonomura.¹
¹Urology, Osaka University Graduate School of Medicine, Suita, Japan; ²Urology, Osaka General Medical Center, Osaka, Japan; ³Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita, Japan.
Objectives: New-onset diabetes after transplantation (NODAT), one of the important complications after kidneytransplantation, leads to reduce graft survival rate and increase patient morbidity and mortality.…